Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiac Catheterization II: Right Heart Catheterization

Cardiac Catheterization II: Right Heart Catheterization

Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Guideline-Directed Medical Therapy Use and Dose Optimization after TAVR in Patients with Persistent HFrEF.

Journal of cardiac failure·2026

Same author

Pregnancy Management and Outcomes with Hypertrophic Cardiomyopathy.

CJC open·2026

Same author

Baroreflex Activation Therapy In Heart Failure-the Barostim-Enabled Neurohormonal Intervention for Improving Treatment of Heart Failure (BENEFIT-HF) Trial Rationale and Design.

Journal of cardiac failure·2026

Same author

Recent updates in the management of atrial fibrillation in patients with cardiac amyloidosis.

Future cardiology·2026

Same author

Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B.

Journal of cardiac failure·2026

Same author

Initiation of Neurohormonal Blockade and Clinical Outcomes in HeartMate 3 LVAD Recipients During Index Implantation.

Artificial organs·2026

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

HeartMate® II continuous-flow left ventricular assist system.

Farooq H Sheikh¹, Stuart D Russell

¹Johns Hopkins Hospital, 600 North Wolfe Street, Carnegie 568, Baltimore, MD 21287, USA.

Expert Review of Medical Devices

|December 17, 2010

Summary

This summary is machine-generated.

Continuous-flow left ventricular assist devices (LVADs) improve survival and reduce complications in advanced heart failure patients. The HeartMate II LVAD offers durable circulatory support for transplant candidates and those ineligible for transplant.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Experiment Videos

Last Updated: Jun 6, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Area of Science:

Cardiology
Biomedical Engineering

Background:

Advanced heart failure necessitates mechanical circulatory support.
Continuous-flow rotary left ventricular assist devices (LVADs) aim for improved durability and fewer complications compared to older models.

Observation:

The HeartMate II continuous-flow left ventricular assist system (LVAS) is a standard of care for long-term mechanical circulatory support.
This device functions effectively as both a bridge to transplantation and destination therapy for heart failure patients.

Findings:

Direct comparison with pulsatile LVADs shows the HeartMate II LVAS improves survival rates.
Implantation of the HeartMate II LVAS leads to a reduction in device-related complications and adverse events.

Implications:

The HeartMate II represents a significant advancement in managing advanced heart failure.
Understanding the technology and clinical outcomes of continuous-flow LVADs is crucial for patient care and future device development.